Peptide news & updates
Follow regulatory developments, research context, and educational explainers without leaving the peptide review cycle to rumor.
regulatory
HHS Announces Draft Peptide Compounding Policy: What Changes, and What Does Not
An October 28 HHS notice outlines a proposed interim 503A pathway. October 30 is a publication date—not a confirmed treatment launch date.
Read more →
regulatory
FDA Advisory Committee Votes to Recommend Six Peptides for Compounding
On July 23-24, 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A bulks list. Emideltide was not recommended.
Read more →
regulatory
FDA Announces July 2026 Advisory Committee for Peptide Review
Ahead of the vote, the FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026 to weigh seven peptides for the 503A bulks list. The committee ultimately recommended six of them.
Read more →
research
BPC-157: What the Research Shows About Gut Healing
BPC-157 remains one of the most discussed regenerative peptides, but the research story is strongest in gastrointestinal protection and ulcerative colitis-related models.
Read more →
education
Research Peptides vs Medical-Grade: Understanding the Difference
The biggest safety variable in peptide therapy is often not the peptide itself, but the quality controls around sourcing, pharmacy standards, and physician oversight.
Read more →